MAFLD but Not MASLD Increases Risk of All-cause Mortality in Regional Australia, with Components of Metabolic Syndrome Exacerbating Factors: 20 year Longitudinal, Cohort Study

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2024 Dec 14

PMID 39673677

Authors

Karl Vaz

William Kemp

Ammar Majeed

John Lubel

Dianna J Magliano

Kristen M Glenister

Lisa Bourke

David Simmons

Stuart K Roberts

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Controversy remains whether the mortality risk in people with fatty liver disease (FLD) including metabolic-(dysfunction) associated steatotic liver disease (MASLD) and metabolic-(dysfunction) associated fatty liver disease (MAFLD) is higher than observed in those without FLD. We aimed to determine the mortality rate and mortality rate ratio (MRR) for these FLDs.

Methods: The study population was a randomly selected cohort of community-dwelling adults in regional Victoria, Australia between 2001 and 2003 with sufficient data evaluable for Fatty Liver Index and determination on alcohol consumption. MASLD and MAFLD were diagnosed by established criteria. The primary outcome was overall mortality and main secondary outcome was major adverse liver outcomes (MALO) (i.e., decompensated liver disease, primary liver cancer and liver-related death). Non-fatal and fatal outcomes were captured via data linkage to hospital admission, cancer registry, and death registries. MRR was calculated with non-FLD participants as the comparator.

Results: 1444 (99.3%) and 1324 (91.1%) individuals from a total of 1454 were included in the final MAFLD and MASLD analyses. The median follow-up was 19.7 years (IQR 19.1-20.1) and there were 298 deaths. The MRR for MAFLD and MASLD was 1.39 (95% CI 1.10-1.76) and 1.25 (95% CI 0.96-1.61), respectively. MAFLD persisted as a risk factor for all-cause death on multivariable models correcting for lifestyle and socioeconomic variables, but not when adjusted for metabolic risk factors. MALOs were increased in MAFLD [incidence rate ratio (IRR) 3.03, 95% CI 1.22-8.18] and MASLD (IRR 2.80, 95% CI 1.05-7.90). Metabolic risk factors increased the risk of overall mortality and MALO, and cancer (34.3-34.6%) and cardiovascular disease (30.1-33.7%) were the most common cause of death in FLD.

Conclusion: In this population-based longitudinal study, MAFLD but not MASLD increases the risk of overall mortality, with metabolic syndrome components key risk factors increasing risk of death.

References

Dong T, Kalani A, Aby E, Le L, Luu K, Hauer M . Machine Learning-based Development and Validation of a Scoring System for Screening High-Risk Esophageal Varices. Clin Gastroenterol Hepatol. 2019; 17(9):1894-1901.e1. DOI: 10.1016/j.cgh.2019.01.025. View

Marchesini G, Brizi M, Morselli-Labate A, Bianchi G, Bugianesi E, McCullough A . Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107(5):450-5. DOI: 10.1016/s0002-9343(99)00271-5. View

Sanyal A, Van Natta M, Clark J, Neuschwander-Tetri B, Diehl A, Dasarathy S . Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021; 385(17):1559-1569. PMC: 8881985. DOI: 10.1056/NEJMoa2029349. View

Adams L, Lymp J, Sauver J, Sanderson S, Lindor K, Feldstein A . The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005; 129(1):113-21. DOI: 10.1053/j.gastro.2005.04.014. View

Lazo M, Hernaez R, Bonekamp S, Kamel I, Brancati F, Guallar E . Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011; 343:d6891. PMC: 3220620. DOI: 10.1136/bmj.d6891. View

Kim D, Konyn P, Sandhu K, Dennis B, Cheung A, Ahmed A . Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021; 75(6):1284-1291. DOI: 10.1016/j.jhep.2021.07.035. View

Younossi Z, Paik J, Al Shabeeb R, Golabi P, Younossi I, Henry L . Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?. Hepatology. 2022; 76(5):1423-1437. DOI: 10.1002/hep.32499. View

Rinella M, Castro Narro G, Krag A, Terrault N, Newsome P . Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease. J Hepatol. 2024; 81(1):e20-e21. DOI: 10.1016/j.jhep.2023.10.008. View

Vaz K, Kemp W, Majeed A, Lubel J, Magliano D, Glenister K . Steatotic liver disease in rural and regional Victoria, according to the NAFLD and newer diagnostic criteria: retrospective cohort analyses of 2001-03 and 2016-18 data. Med J Aust. 2023; 220(2):97-99. DOI: 10.5694/mja2.52189. View

10.

Song S, Lai J, Wong G, Wong V, Yip T . Can we use old NAFLD data under the new MASLD definition?. J Hepatol. 2023; 80(2):e54-e56. DOI: 10.1016/j.jhep.2023.07.021. View

11.

Devers M, Campbell S, Shaw J, Zimmet P, Simmons D . Should liver function tests be included in definitions of metabolic syndrome? Evidence from the association between liver function tests, components of metabolic syndrome and prevalent cardiovascular disease. Diabet Med. 2008; 25(5):523-9. DOI: 10.1111/j.1464-5491.2008.02408.x. View

12.

Simmons D, McKenzie A, Eaton S, Shaw J, Zimmet P . Prevalence of diabetes in rural Victoria. Diabetes Res Clin Pract. 2005; 70(3):287-90. DOI: 10.1016/j.diabres.2005.04.004. View

13.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A . The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006; 6:33. PMC: 1636651. DOI: 10.1186/1471-230X-6-33. View

14.

Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M . A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020; 73(1):202-209. DOI: 10.1016/j.jhep.2020.03.039. View

15.

ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S19-S40. PMC: 9810477. DOI: 10.2337/dc23-S002. View

16.

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

17.

Castera L, Friedrich-Rust M, Loomba R . Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019; 156(5):1264-1281.e4. PMC: 7505052. DOI: 10.1053/j.gastro.2018.12.036. View

18.

Kechagias S, Nasr P, Blomdahl J, Ekstedt M . Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism. 2020; 111S:154183. DOI: 10.1016/j.metabol.2020.154183. View

19.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

20.

Liu Y, Zhong G, Tan H, Hao F, Hu J . Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep. 2019; 9(1):11124. PMC: 6668400. DOI: 10.1038/s41598-019-47687-3. View